Research summary ·
Definition and prevalence of residual disease in inflammatory arthritis: a systematic literature review and meta-analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at how residual disease is defined in inflammatory arthritis. It covered rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (RA, PsA and axSpA). Residual disease means signs or symptoms that remain after targets are met. The team also estimated how common and how severe it is. They pooled studies by indicator when they could.
What they found
59 studies covered definitions. Disease states were almost all based on disease activity. Tools and cutoffs varied a lot. Doctor and patient reports were used more than lab tests. Pain, CRP and joint counts were common choices. 84 studies covered how common it is. It was notable. Some in remission still had swollen joints in RA and PsA. Up to a third had pain or fatigue. Evidence for axSpA was limited.
What it means for patients
The authors say definitions vary a lot. They say residual disease can affect a large share of patients. They say a consensus definition is needed.
Why it is not certain yet
Definitions varied a lot across studies. Evidence for axSpA was limited. It gives no pooled figure for each disease.
Source
Definition and prevalence of residual disease in inflammatory arthritis: a systematic literature review and meta-analysis.
PubMed · PMID 42485861We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Psoriatic arthritis publications